Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation

News

January 29, 2024
PRESS RELEASE: On January 24, 2024, a new research perspective was published in Oncotarget, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.” continue reading »

New Drug May Boost Effectiveness of Glioblastoma Treatment

Trending

January 25, 2024
In a new study, researchers investigated the activity of gartisertib, a potent ATR inhibitor, alone and in combination with standard therapy in multiple glioblastoma cell lines. continue reading »

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease

News

January 24, 2024
PRESS RELEASE: On January 16, 2024, a new case report was published in Oncotarget, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.” continue reading »

Bone Marrow Adipocytes Provide Early Sign of Progression from MGUS to Multiple Myeloma

News

January 22, 2024
PRESS RELEASE: On January 16, 2024, a new research perspective was published in Oncotarget, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.” continue reading »

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines

News

January 17, 2024
PRESS RELEASE: On January 16, 2024, a new research paper was published in Oncotarget, entitled, “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.” continue reading »